このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Endo International は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。

シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。

業績と収益の成長予測

OTCPK:ENDP.Q - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2023	2,012	-2,448	341	435	N/A
9/30/2023	2,070	-252	334	430	N/A
6/30/2023	2,160	-942	285	391	N/A
3/31/2023	2,182	-2,847	21	130	N/A
12/31/2022	2,319	-2,910	166	269	N/A
9/30/2022	2,552	-3,221	11	110	N/A
6/30/2022	2,783	-2,552	-9	80	N/A
3/31/2022	2,928	-681	277	369	N/A
12/31/2021	2,993	-569	326	411	N/A
9/30/2021	2,964	129	484	569	N/A
6/30/2021	2,827	109	345	429	N/A
3/31/2021	2,801	137	506	579	N/A
12/31/2020	2,903	247	327	402	N/A
9/30/2020	2,908	-102	195	268	N/A
6/30/2020	3,002	-75	299	378	N/A
3/31/2020	3,014	-190	180	251	N/A
12/31/2019	2,914	-361	30	98	N/A
9/30/2019	2,936	-418	108	190	N/A
6/30/2019	2,952	-522	63	135	N/A
3/31/2019	2,967	-477	47	128	N/A
12/31/2018	2,947	-962	177	267	N/A
9/30/2018	2,929	-968	238	329	N/A
6/30/2018	2,971	-921	324	434	N/A
3/31/2018	3,132	-1,565	311	435	N/A
12/31/2017	3,469	-1,233	428	554	N/A
9/30/2017	3,942	-4,294	N/A	507	N/A
6/30/2017	4,039	-4,386	N/A	309	N/A
3/31/2017	4,084	-3,300	N/A	742	N/A
12/31/2016	4,010	-3,224	N/A	528	N/A
9/30/2016	3,842	553	N/A	683	N/A
6/30/2016	3,704	-59	N/A	698	N/A
3/31/2016	3,518	-539	N/A	106	N/A
12/31/2015	3,269	-300	N/A	119	N/A
9/30/2015	2,858	-725	N/A	-75	N/A
6/30/2015	2,766	128	N/A	310	N/A
3/31/2015	2,624	260	N/A	492	N/A
12/31/2014	2,381	58	N/A	338	N/A
9/30/2014	2,303	-643	N/A	277	N/A
6/30/2014	2,310	-637	N/A	141	N/A
3/31/2014	2,429	-650	N/A	124	N/A
12/31/2013	2,125	189	N/A	299	N/A
9/30/2013	2,621	-628	N/A	711	N/A
6/30/2013	2,711	-629	N/A	683	N/A

アナリストによる今後の成長予測

収入対貯蓄率: ENDP.Qの予測収益成長が貯蓄率 ( 2.4% ) を上回っているかどうかを判断するにはデータが不十分です。

収益対市場: ENDP.Qの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です

高成長収益: ENDP.Qの収益が今後 3 年間で大幅に増加すると予想されるかどうかを判断するにはデータが不十分です。

収益対市場: ENDP.Qの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

高い収益成長: ENDP.Qの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ENDP.Qの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Endo International 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Price target decreased to US$2.63

Price target decreased to US$6.17

Price target decreased to US$6.57

Consensus forecasts updated

Price target raised to US$7.45

Price target raised to US$6.91

Recent updates

Endo International plc to Report Q1, 2024 Results on May 30, 2024

Fourth Amended Reorganization Plan Filed by Endo International plc

Endo International plc to Report Q3, 2023 Results on Nov 06, 2023

Endo International plc, Annual General Meeting, Sep 07, 2023

Endo International plc Launches First Generic Version of Noxafil® (posaconazole) Injection

Endo International plc Announces First Patient Enrolled in Registry of Dupuytren's Contracture

Endo International plc Launches PREVDUO (Neostigmine Mylsulfate and Glycopyrrolate Injection), the First and Only FDA-Approved Neostigmine-Glycopyrrolate Combination Pre-Filled Syringe

Two Affiliate Companies Joined Endo International plc Bankruptcy

Endo International plc Announces Asset Impairment Charges for Three Months Ended March 31, 2023

Endo International plc and SMSNA Launches App to Provide Peyronie's Disease Self-Assessment Tool

Nasdaq to Delist Common Stock of Endo International

Endo International Provides Delisting Update

Endo International plc(NasdaqGS:ENDP) dropped from NASDAQ Biotechnology Index

Endo International plc(NasdaqGS:ENDP) dropped from S&P TMI Index

Endo International plc Filed for Bankruptcy

Endo International plc Filed for Bankruptcy

Endo creditors looking at putting company up for sale through bankruptcy - Bloomberg

Second quarter 2022 earnings released: US$8.00 loss per share (vs US$0.044 loss in 2Q 2021)

Endo International sees 23% rise on 3x higher than normal volume

Endo outperforms defying bankruptcy fears and generic entry

Endo weighs bankruptcy filing without opioid settlement - WSJ

Endo International Receives Non-Compliance Notice from Nasdaq

Endo International cools off, giving back some of its 85% Tuesday gain

Endo International plc(NasdaqGS:ENDP) dropped from S&P Pharmaceuticals Select Industry Index

Endo: Stick A Fork In It

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Endo Aesthetics to Introduce New Clinical Study of Qwo® (collagenase clostridium histolyticum-aaes) at the Annual SCALE Meeting

Price target decreased to US$2.63

Endo International plc to Report Q1, 2022 Results on May 05, 2022

Edesa Biotech, Inc. Appoints Jennifer M. Chao to its Board of Directors

Endo Begins Shipment of Premixed Ephedrine Sulfate Injection in Ready-To-Use Vials

Endo: About As Bad As It Gets

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Endo International plc Announces Launch of Ready-to-Use VASOSTRICT® (vasopressin injection, USP) in Pre-Mix Bottles

Endo Announces Publication of New AVEED® (testosterone undecanoate) Data in Peer-Reviewed Journal of Clinical Pharmacology; Data Evaluates Dosing Flexibility in Men With Hypogonadism

Price target decreased to US$6.17

Endo: FDA Approves Generic Form Of Vasostrict Creating Headwind Into Next Year

Investor sentiment deteriorated over the past week

Endo International plc Announces its Qwo (Collagenase Clostridium Histolyticum-Aaes) Data Presented at the American Society for Dermatologic Surgery's Annual Meeting

Third quarter 2021 earnings released: US$0.21 loss per share (vs US$0.30 loss in 3Q 2020)

Investor sentiment improved over the past week

Endo: A Win In California But Equity Value Still A Question

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Price target decreased to US$6.57

Endo International: Loses Vasostrict Trial

Investor sentiment deteriorated over the past week

Endo International: Hires Restructuring Advisor

Consensus forecasts updated

Endo International: All About Ongoing Litigation

Second quarter 2021 earnings released: US$0.044 loss per share (vs US$0.077 profit in 2Q 2020)

Investor sentiment improved over the past week

Endo: Appellate Court Denies Request To Postpone Damages Trial Might Be End O' The Road

Investor sentiment deteriorated over the past week

Endo International: Bankruptcy Seems Like The Only Practical Option

Endo International plc(NasdaqGS:ENDP) dropped from Russell 2500 Growth Index

Endo International wins FDA approval for Micafungin new formulation

Chairman Paul Campanelli has left the company

Senior Independent Director Roger Kimmel has left the company

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS US$0.20 (vs US$0.69 in 1Q 2020)

Endo International plc Announces Asset Impairment Results for the First Quarter Ended March 31, 2021

Endo International plc 2021 Q1 - Results - Earnings Call Presentation

Chairman exercised options and sold US$1.4m worth of stock

Investor sentiment deteriorated over the past week

Independent Director recently sold US$150k worth of stock

Investor sentiment deteriorated over the past week

Price target raised to US$7.45